Information Provided By: 
Fly News Breaks for March 2, 2017
PCRX
Mar 2, 2017 | 09:08 EDT
Janney Capital analyst Ken Trbovich downgraded Pacira to Sell from Neutral, statin that its guidance suggests no meaningful change in the outlook for Exparel sales this year. While the company also announced positive results from its Phase 4 study of Exparel in total knee replacement surgery, it may take "years" for the company to fully exploit this commercially, said Trbovich, who raised his fair value estimate on the stock to $38 from $34.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
